Association between enhancement patterns and parameters of contrast‑enhanced ultrasound and microvessel distribution in breast cancer

Li, Xiaokang; Li, Yaqing; Zhu, Ying; Fu, Li; Liu, Peifang

doi:10.3892/ol.2018.8078

Cited by 22 publications

(24 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The correlation exhibited a significant difference ( P =0.0073). This conclusion was similar to the result ( r =0.267, P =0.017) based on a clinical study led by Li et al 34 Thus, the dynamic variation of the parameters of CEUS can reflect the progress of vascular normalization to a certain extent.…”

Section: Discussionsupporting

confidence: 90%

Clinical evaluation of vascular normalization induced by recombinant human endostatin in nasopharyngeal carcinoma via dynamic contrast-enhanced ultrasonography

Yang¹,

Kang²,

Zhu³

et al. 2018

OTT

View full text Add to dashboard Cite

BackgroundThe present study confirmed the presence and exact range of “vascular normalization window” induced by recombinant human endostatin (RHES) in patients with nasopharyngeal carcinoma (NPC) by analyzing the variation of dynamic contrast-enhanced ultrasonography (DCE-US) quantitative parameters. Also, the clinical application of DCE-US in the evaluation of vascular normalization was assessed.Materials and methodsA total of 30 previously untreated patients with stage III–IVA NPC were enrolled in the present study and were randomly but equally divided into RHES (endostar [ES]) and normal saline (NS) groups. The patients in the ES group were administered RHES intravenously, while the patients in the NS group were administered normal saline daily for 5 days prior to intensity modulated radiotherapy coupled with concurrent chemotherapy. All patients underwent DCE-US on the day before the administration and on days 3 and 5 subsequently. The Audio Video Interleave of each DCE-US examination was analyzed quantitatively using the CHI-Q software. Several parameters were investigated, such as peak intensity (PI), time to peak (TTP), and mean transit time (MTT).ResultsThe PI, TTP, and MTT differed significantly at the three time points in the ES group (all P<0.001) but not in the NS group (all P>0.05). In the ES group, PI increased and subsequently decreased, whereas TTP, as well as MTT, lessened initially and then increased within the 5 days after administration of RHES. The maximum value of PI and the minimum value of TTP, as well as MTT, occurred on day 3 (all P<0.05). Furthermore, the values of PI, TTP, and MTT were similar prior to the administration of RHES in both groups (all P>0.05). However, the PI of the ES group was significantly higher (P<0.05), whereas the TTP and the MTT were significantly lower following administration of RHES (all P<0.05) compared with the corresponding parameters of the NS group.ConclusionDCE-US is a suitable method for the clinical evaluation of vascular normalization induced by antiangiogenic agents. The “vascular normalization window” induced by RHES occurs in patients with NPC, and the exact range is within about 5 days post-administration, which contributes towards optimizing the modality of RHES combined with radiotherapy and chemotherapy for NPC patients.

show abstract

Section: Discussionsupporting

confidence: 90%

Clinical evaluation of vascular normalization induced by recombinant human endostatin in nasopharyngeal carcinoma via dynamic contrast-enhanced ultrasonography

Yang¹,

Kang²,

Zhu³

et al. 2018

OTT

View full text Add to dashboard Cite

show abstract

“…CEUS represents a method with good prospects for the early diagnosis of breast diseases and could be helpful to optimize the BI-RADS category 16,19. The enhancement patterns of lesions may be influenced by multiple factors such as microvessel density (MVD) and the intercellular substance structure 20. How to improve the diagnostic performance of CEUS is still an issue in the clinical application of CEUS.…”

Section: Discussionmentioning

confidence: 99%

<p>A multicenter study of a contrast-enhanced ultrasound diagnostic classification of breast lesions</p>

Tang

Chen

et al. 2019

CMAR

View full text Add to dashboard Cite

PurposeTo evaluate a classification model of contrast-enhanced ultrasound (CEUS) and examine the characteristics of patients with false-negative diagnosis.Patients and methodsA retrospective secondary analysis of a multicenter trial of CEUS for breast cancer diagnosis (from August 2015 to April 2017) was undertaken. Patients (n=1,023) with Breast Imaging Reporting and Data System 4–5 lesions on B-mode ultrasound underwent CEUS. Pathological diagnoses were available from surgical or biopsy specimens for correlation. Lesion maximum diameter (LMD), distance to the papilla (DtP), distance from the superficial edge of the lesion to the skin (DtS), distance from the deep edge of the lesion to the pectoralis muscle (DtPM), and body mass index (BMI) were evaluated.ResultsMedian age and BMI were 48.0 and 41.2 years and 23.2 and 22.4 kg/m2 for patients with malignant and benign lesions, respectively. Overall sensitivity, specificity, and accuracy of CEUS for malignancy were 89.4%, 65.3%, and 75.8%, respectively. The patients with true-positive and false-negative diagnosis (ie, with malignant lesion) were older than those with false-positive and true-negative diagnosis (ie, with benign lesion). Patients with true-positive and false-positive diagnoses had higher BMI than patients with true-negative and false-negative diagnoses (P=0.004). Patients with true-positive and false-negative diagnoses had larger LMD and DtP, as well as smaller DtS and DtPM.ConclusionOlder age, higher BMI, larger LMD and DtP, and smaller DtS and DtPM were associated with malignant lesions on CEUS. Patients with these characteristics should undergo further imaging.

show abstract

“…The enhancement is heterogeneous and perilesional due to a higher peripheral/central ratio of microvessel density, compared to tumors with a lower histological grade. There is also a difference regarding the rise time (RT) and TTP ( Table 4 ) [ 14 , 26 , 34 ].…”

Section: Correlation Between Prognostic Factors and Ceus Charactermentioning

confidence: 99%

Contrast-Enhanced Ultrasonography in the Diagnosis and Treatment Modulation of Breast Cancer

Boca

Dudea

Ciurea

2021

JPM

View full text Add to dashboard Cite

The aim of this paper is to highlight the role of contrast-enhanced ultrasound in breast cancer in terms of diagnosis, staging and follow-up of the post-treatment response. Contrast-enhanced ultrasound (CEUS) is successfully used to diagnose multiple pathologies and has also clinical relevance in breast cancer. CEUS has high accuracy in differentiating benign from malignant lesions by analyzing the enhancement characteristics and calculating the time-intensity curve’s quantitative parameters. It also has a significant role in axillary staging, especially when the lymph nodes are not suspicious on clinical examination and have a normal appearance on gray-scale ultrasound. The most significant clinical impact consists of predicting the response to neoadjuvant chemotherapy, which offers the possibility of adjusting the therapy by dynamically evaluating the patient. CEUS is a high-performance, feasible, non-irradiating, accessible, easy-to-implement imaging method and has proven to be a valuable addition to breast ultrasound.

show abstract

Association between enhancement patterns and parameters of contrast‑enhanced ultrasound and microvessel distribution in breast cancer

Cited by 22 publications

References 20 publications

Clinical evaluation of vascular normalization induced by recombinant human endostatin in nasopharyngeal carcinoma via dynamic contrast-enhanced ultrasonography

Clinical evaluation of vascular normalization induced by recombinant human endostatin in nasopharyngeal carcinoma via dynamic contrast-enhanced ultrasonography

<p>A multicenter study of a contrast-enhanced ultrasound diagnostic classification of breast lesions</p>

Contrast-Enhanced Ultrasonography in the Diagnosis and Treatment Modulation of Breast Cancer

Contact Info

Product

Resources

About